Download PDF
Thromb Haemost 1981; 45(01): 065-067
DOI: 10.1055/s-0038-1650130
Original Article
Schattauer GmbH Stuttgart

Plasma Prekallikrein and Endotoxemia in Liver Cirrhosis

A C M van Vliet
The Department of Internal Medicine II, Hematology and Clinical Microbiology of the Erasmus University, Rotterdam, The Netherlands
,
H H D M van Vliet
The Department of Internal Medicine II, Hematology and Clinical Microbiology of the Erasmus University, Rotterdam, The Netherlands
,
G Džoljić-Danilović
The Department of Internal Medicine II, Hematology and Clinical Microbiology of the Erasmus University, Rotterdam, The Netherlands
,
J H P Wilson
The Department of Internal Medicine II, Hematology and Clinical Microbiology of the Erasmus University, Rotterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 16 July 1980

Accepted 16 December 1980

Publication Date:
04 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

In liver disease low prekallikrein levels may be found which has been suggested to be due to diminished synthesis. However, it may also be due to endotoxemia accompanying liver disease. To study the last possibility prekallikrein, endotoxins and Normotest were determined in 18 cirrhosis patients. The relation between the prekallikrein concentration (after 15 min activation) and the Normotest was significant (r = +0.72, P <0.001). Endotoxemia was only found in the more severe forms of liver disease (Normotest below 60%). During endotoxemia the prekallikrein levels were significantly lower than when no endotoxins were present in the blood of the same patients. The Normotest did not differ significantly in these patients in relation to the presence or absence of endotoxins. The activation of prekallikrein was slower in the more severe forms of liver disease. This might be due to reduced levels of factor XII and high molecular weight kininogen.

Keywords

Prekallikrein - Prekallikrein activation - Normotest - Endotoxin - Cirrhosis - Liver disease
 

  • References

  • 1 Chan JY C, Habal FM, Burrowes CE, Movat HZ. Interaction between factor XII (Hageman factor), high molecular weight kininogen and prekallikrein. Thromb Res 1976; 09: 423-433
    CrossrefPubMedGoogle Scholar
  • 2 Clemente C, Bosch J, Rodés J, Arroyo V, Mas A, Maragall S. Functional renal failure and haemorrhagic gastritis associated with endotoxemia in cirrhosis. Gut 1977; 18: 556-560
    CrossrefPubMedGoogle Scholar
  • 3 Cochrane CG, Griffin JH. Molecular assembly in the contact phase of the Hageman factor system. Am J Med 1979; 67: 657-664
    CrossrefPubMedGoogle Scholar
  • 4 Cooperstock MS, Tucker RP, Baublis JV. Possible pathogenetic role of endotoxin in Reye’s syndrome. Lancet 1975; 01: 1272-1274
    PubMedGoogle Scholar
  • 5 Elin RJ, Wolff SM. Biology of endotoxin. Annu Rev Med 1976; 27: 127-141
    CrossrefPubMedGoogle Scholar
  • 6 Friberger P, Eriksson E, Gustavsson S, Cleason G. Determination of prekallikrein in plasma by means of a chromogenic tripeptide substrate for plasma kallikrein. Adv Exp Med Biol 1979; 120A: 67-82
    PubMedGoogle Scholar
  • 7 Fujii M, Yasunaga K, Uchino H. Correlation analysis of relationships between vitamin-K-dependent clotting factors and effective hepatic blood flow, albumin and other liver function tests. Haemostasis 1980; 09: 09-14
    PubMedGoogle Scholar
  • 8 Kaplan AP, Austen KF. A pre-albumin activation of prekallikrein. J Immunol L970;105: 802-81L and J Exp Med 1971; 133: 696-712
    CrossrefPubMedGoogle Scholar
  • 9 Kluft C. Blood fibrinolysis. Proactivators and activators in human plasma. Thesis; Leiden: 1978
    Google Scholar
  • 10 Mandle RJ, Colman RW, Kaplan AP. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc Natl Acad Sci USA 1976; 73: 4179-4183
    CrossrefPubMedGoogle Scholar
  • 11 Meier HL, Pierce JV, Colman RW, Kaplan AP. Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein. J Clin Invest 1977; 60: 18-31
    CrossrefPubMedGoogle Scholar
  • 12 Morrison DC, Cochrane CG. Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). J Exp Med 1974; 140: 797-811
    CrossrefPubMedGoogle Scholar
  • 13 Poller L. Coagulation abnormalities in liver disease. In: Poller L. ed. Recent advances in blood coagulation. Edinburgh: Churchill Livingstone; 1977. 267-292
    Google Scholar
  • 14 Robinson JA, Klodnycky ML, Loeb HS, Racic MR, Gunnar RM. Endotoxin, prekallikrein, complement and systemic vascular resistance. Sequential measurements in man. Am J Med 1975; 59: 61-67
    CrossrefPubMedGoogle Scholar
  • 15 Saito H. Determination of Hageman factor (HG, factor XII) and plasma prekallikrein (Fletcher factor) by radioimmunoassays. Adv Exp Med Biol 1979; 120A: 165-172
    PubMedGoogle Scholar
  • 16 Saito H, Poon MC, Vide W, Goldsmith GH, Menitove JE. Human plasma prekallikrein (Fletcher factor) clotting activity and antigen in health and disease. J Lab Clin Med 1978; 92: 84-95
    PubMedGoogle Scholar
  • 17 Stormorken H, Baklund A, Gallimore M, Ritland S. Chromogenic substrate assay of plasma prekallikrein. Haemostasis 1978; 07: 69-75
    PubMedGoogle Scholar
  • 18 Van Vliet ACM, Maas HC M, Wilson JH P. The effect of portasystemic shunting and RES function on endotoxemia in human liver disease. In: Liehr H, Grün M. eds. The reticuloendothelial system and the pathogenesis of liver. Amsterdam: Elsevier/ North-Holland, Biomedical; 1980. 159-164
    Google Scholar
  • 19 Wong PY. The kallikrein-kinin and related vasoactive systems in cirrhosis of the liver. In: Epstein M. ed. The kidney in liver disease. New York: Elsevier; 1978. 299-310
    Google Scholar